Seasoned growth-stage investor and operating executive with experience across technology and healthcare investing, portfolio company operations, and capital raising. Chad Tobin brings a background blending corporate development, venture capital and hands-on operational leadership, often focusing on revenue scaling, go-to-market execution and M&A. Known for structuring growth equity investments and board-level oversight, works with founders and LPs to align strategic plans and exit pathways. Active in North American middle-market transactions.
Seasoned growth-stage investor and operating executive with experience across technology and healthcare investing, portfolio company operations, and capital raising. Chad Tobin brings a background blending corporate development, venture capital and hands-on operational leadership, often focusing on revenue scaling, go-to-market execution and M&A. Known for structuring growth equity investments and board-level oversight, works with founders and LPs to align strategic plans and exit pathways. Active in North American middle-market transactions.
Focuses on growth‑equity investments in North American middle‑market technology and healthcare companies, prioritizing revenue scaling, repeatable go‑to‑market models and strategic M&A to accelerate exits. Capital allocation favors lead or syndicate positions that provide board seats and operational influence; horizon is multi‑year, value‑creation driven. Underwrites companies by pairing revenue and unit economics momentum with disciplined downside protections. Investment edge derives from hands‑on operating experience, rigorous commercial KPIs and founder/LP alignment.
Focuses on growth‑equity investments in North American middle‑market technology and healthcare companies, prioritizing revenue scaling, repeatable go‑to‑market models and strategic M&A to accelerate exits. Capital allocation favors lead or syndicate positions that provide board seats and operational influence; horizon is multi‑year, value‑creation driven. Underwrites companies by pairing revenue and unit economics momentum with disciplined downside protections. Investment edge derives from hands‑on operating experience, rigorous commercial KPIs and founder/LP alignment.
| Trades 1466 | Longs Won 1042/1466 71% | Profit Factor 7.21 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $428,911.12 |
| Average Win $138,115.63 | Best Trade (Oct 14) $10.49M | Sharpe Ratio -12.61 |
| Average Loss -$47,062.19 | Worst Trade (Oct 14) -$1.06M | Z-Score 8.06 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 1w 1d | Expectancy $84,558.07 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 7,299 | 6,569 | 5,839 | 5,109 | 4,380 | 3,650 | 2,920 | 2,190 | 1,460 | 730 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 59,079 | $11.93M | $20.46M | - | $8.53M | 71.56% | +1.259% |
ABBV AbbVie Inc. | 5,092 | $806,521.58 | $1.44M | - | $637,467.78 | 79.04% | +0.064% |
ABT Abbott Laboratories | 3,572 | $391,838.1 | $376,649.54 | - | -$15,188.56 | -3.88% | +0.731% |
ACN Accenture plc Class A | 23,203 | $2.89M | $5.34M | - | $2.45M | 85% | +2.354% |
AEE Ameren Corporation | 3,729 | $289,770.09 | $388,505.86 | - | $98,735.77 | 34.07% | +0.419% |
AEP American Electric Power Company, Inc. | 23,546 | $3.22M | $2.94M | - | -$283,144.39 | -8.79% | +0.398% |
AES AES Corporation | 182,294 | $2.05M | $2.73M | - | $680,902.32 | 33.28% | 0.0 |
AGEM Abrdn Emerging Market Dividend Allocator ETF | 5,054 | $194,003.33 | $232,610.35 | - | $38,607.02 | 19.9% | -0.658% |
AIS VistaShares Artificial Intelligence Supercycle ETF | 4,282 | $365,297 | $365,297 | - | - | - | 0.0 |
AMAT Applied Materials, Inc. | 1,262 | $249,709.21 | $532,904.74 | - | $283,195.53 | 113.41% | -1.8% |
AMD Advanced Micro Devices, Inc. | 1,128 | $182,918.24 | $619,926.24 | - | $437,008 | 238.91% | -2.25% |
AMGN Amgen Inc. | 9,098 | $2.65M | $3.96M | - | $1.31M | 49.45% | +0.402% |
AMT American Tower Corporation | 22,744 | $3.72M | $4.13M | - | $407,170.4 | 10.94% | +0.063% |
AMZN Amazon.com Inc | 5,237 | $887,509.91 | $1.33M | - | $446,799.13 | 50.34% | +0.01% |
AVEM Avantis Emerging Markets Equity ETF | 27,844 | $2.04M | $2.52M | - | $478,264.07 | 23.46% | -0.681% |
AVGO Broadcom Inc. | 17,221 | $3.9M | $5.81M | - | $1.91M | 49.04% | -1.978% |
AVUV Avantis U.S. Small Cap Value ETF | 6,172 | $541,440.74 | $746,558.95 | - | $205,118.21 | 37.88% | +0.431% |
BA Boeing Company | 1,151 | $272,719.48 | $218,770.57 | - | -$53,948.91 | -19.78% | +0.71% |
BAC Bank of America Corporation | 83,540 | $3.13M | $4.33M | - | $1.2M | 38.46% | +0.29% |
BBY Best Buy Co., Inc. | 59,759 | $4.53M | $5.7M | - | $1.17M | 25.71% | +1.296% |